The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Challenges & potential solutions for balancing efficacy and tolerability in older patients with CLL
Florian Simon, MD, University Hospital Cologne, Cologne, Germany, shares his thoughts on the challenges and potential solutions for balancing efficacy and tolerability in older patients with chronic lymphocytic leukemia (CLL). Dr Simon suggests that combining therapies or implementing measurable residual disease (MRD) assessments to shorten therapy duration could be effective. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
